GNE-493 is a potent, selective and orally available pan-PI3-kinase and dual pan-PI3-kinase/mTOR inhibitor for the treatment of cancer. The PI3K/AKT/mTOR pathway has been shown to play an important role in cancer. GNE-493 is highly selective, demonstrate knock down of pathway markers in vivo, and is efficacious in xenograft models where the PI3K pathway is deregulated.
|Cell lines||PC3 and MCF7.1 cells|
|Preparation method||Antiproliferative cellular assays were conducted using PC3 and MCF7.1 human tumor cell lines provided by the ATCC or Genentech Research laboratories, respectively. MCF7.1 is an in vivo selected line developed at Genentech and originally derived from the parental human MCF7 breast cancer cell line (ATCC, Manassas, VA). Cell lines were cultured in RPMI supplemented with 10% fetal bovine serum, 100 units/mL penicillin, and 100 μg/mL streptomycin, 10 mM HEPES, and 2 mM glutamine at 37 C under 5% CO2. MCF7.1 cells or PC3 cells were seeded in 384-well plates in media at 1000 cells/well or 3000 cells/well, respectively, and incubated overnight prior to the addition of compounds to a final DMSO concentration of 0.5% v/v. MCF7.1 cells and PC3 cells were incubated for 3 and 4 days, respectively, prior to the addition of CellTiter-Glo reagent (Promega) and reading of luminescence using an Analyst plate reader.|
|Incubation time||3 and 4 days|
|Animal models||Nu/nu(nude) female mice bearing PC3 prostate cancer xenografts|
|Formulation||0.5% methylcellulose/0.2% Tween-80|
|Dosages||10mg/kg daily for 14 days|
|Solubility (25°C)||DMSO ≥ 35 mg/mL|
Powder -20°C 3 years ; 4°C 2 years
In solvent -80°C 6 months ; -20°C 1 month
|Body Surface Area (m2)||0.007||0.025||0.15||0.05||0.02||0.5|
|Animal A (mg/kg) = Animal B (mg/kg) multiplied by||Animal B Km|
|Animal A Km|
For example, to modify the dose of Compound A used for a mouse (20 mg/kg) to a dose based on the BSA for a rat, multiply 20 mg/kg by the Km factor for a mouse and then divide by the Km factor for a rat. This calculation results in a rat equivalent dose for Compound A of 10 mg/kg.
 Sutherlin DP, et al. J Med Chem. Discovery of (thienopyrimidin-2-yl)aminopyrimidines as potent, selective, and orally available pan-PI3-kinase and dual pan-PI3-kinase/mTOR inhibitors for the treatment of cancer.
|Related PI3K Products|
STX-478 is a mutation-selective variant PI3Ka inhibitor for studies related to breast cancer and other solid tumors.
Hirsutenone is an active botanical diarylheptanoid present in Alnus species and exhibits many biological activities, including anti-inflammatory, anti-tumor promoting and anti-atopic dermatitis effects. Hirsutenone attenuates adipogenesis by binding directly to PI3K and ERK1 in a non-ATP competitive manner.
Boc-L-cyclobutylglycine is a glycine derivative that can be used for PI3K inhibitor synthesis.
PI-273 is a first reversibly and specific phosphatidylinositol 4-kinase (PI4KIIα) inhibitor with an IC50 of 0.47 μM. PI-273 can inhibit breast cancer cell proliferation, block the cell cycle and induce cell apoptosis.
Chaetominine is an alkaloidal metabolite. Chaetominine has cytotoxicity against human leukemia K562 and colon cancer SW1116 cell lines. Chaetominine reduces MRP1-mediated agent resistance via inhibiting PI3K/Akt/Nrf2 signaling pathway in K562/Adr human leukemia cells.
Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2023 AbMole BioScience. All Rights Reserved.